Everest Medicines (1952) Announces Virtual EGM Agenda and Share Schemes

Bulletin Express02-03

Everest Medicines Limited (Stock Code: 1952) has issued a notice of an Extraordinary General Meeting (EGM) scheduled for Tuesday, 24 February 2026 at 10:00 a.m., to be conducted virtually. Shareholders can access the EGM through an online platform without physical attendance requirements.

According to the notice, several key resolutions will be presented:

First, consideration of the commercialization service agreement dated 11 December 2025 between Everest Medicines (China) Co., Ltd. and Hasten Biopharmaceutical Co., Ltd., along with the related transactions. If approved, certain directors, excluding one specified director, are authorized to execute the necessary documents and actions.

Second, consideration of granting 530,303 awards to a director under the Pre-IPO employee equity plan adopted on 25 December 2018. If approved, other directors are authorized to allot and issue shares in line with this proposed award, ranking pari passu with existing shares upon issuance.

Third, consideration of adopting a 2026 Share Scheme with a scheme mandate limit of 10% of total issued shares (excluding treasury shares) as of the EGM’s approval date. The scheme allows for the granting of awards, with the board and a scheme administrator authorized to implement all related tasks.

Fourth, conditional upon approval of the 2026 Share Scheme, the EGM will consider approving a service provider sublimit of 0.5% of total issued shares (excluding treasury shares) for any awards granted to service providers. If the 2026 Share Scheme is passed but the service provider sublimit is not, references to service providers will be removed. If the sublimit is passed but the main scheme is not, the 2026 Share Scheme will not be adopted.

The notice specifies that shareholders intending to vote must have their share transfers lodged by 4:30 p.m. on Friday, 13 February 2026, and that the register of members closes from 16 February 2026 to 24 February 2026 (both dates inclusive). Shareholders may forward relevant inquiries in advance, and additional details on electronic participation and login are provided in the company’s circular.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment